The Development of ADS-5102 (Amantadine ER Capsules) for the Treatment of Levodopa-induced Dyskinesia

被引：0
作者：
McClure, Natalie [1 ]
机构：
[1] Adamas Pharmaceut Inc, Emeryville, CA USA
来源：
NEUROTHERAPEUTICS | 2015年 / 12卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：679 / 680
页数：2
相关论文
共 50 条
  • [21] POOLED ANALYSIS OF PHASE 3 STUDIES OF ADS-5102 FOR LEVODOPA-INDUCED DYSKINESIA: A DETAILED REVIEW OF MDS-UPDRS, PART IV (MOTOR COMPLICATIONS)
    Tanner, C.
    Pahwa, R.
    Elmer, L.
    Isaacson, S.
    Johnson, R.
    Felt, L.
    Patni, R.
    [J]. PARKINSONISM & RELATED DISORDERS, 2018, 46 : E20 - E20
  • [22] Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson's disease patients
    Pahwa, R.
    Garrison, L.
    Zimmerman, M.
    Johnson, R.
    Nguyen, J.
    Li, M.
    Patni, R.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S398 - S398
  • [23] Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
    Sharma, Vibhash D.
    Lyons, Kelly E.
    Pahwa, Rajesh
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 665 - 673
  • [24] Extended-Release Amantadine for Levodopa-Induced Dyskinesia
    Dashtipour, Khashayar
    Tafreshi, Ali R.
    Pahwa, Rajesh
    Lyons, Kelly E.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (04) : 293 - 299
  • [25] Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
    Lawrence W. Elmer
    Jorge L. Juncos
    Carlos Singer
    Daniel D. Truong
    Susan R. Criswell
    Sotirios Parashos
    Larissa Felt
    Reed Johnson
    Rajiv Patni
    [J]. CNS Drugs, 2018, 32 : 399 - 400
  • [26] Treatment of levodopa-induced dyskinesia
    Rao J.
    [J]. Current Treatment Options in Neurology, 2007, 9 (3) : 205 - 209
  • [27] ADS-5102 provided reduction in motor complications in Parkinson's disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2)
    Isaacson, S.
    Pahwa, R.
    Tanner, C.
    Fahn, S.
    Espay, A.
    Trenkwalder, C.
    Patni, R.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 355 - 355
  • [28] Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102
    Isaacson, Stuart H.
    Fahn, Stanley
    Pahwa, Rajesh
    Tanner, Caroline M.
    Espay, Alberto J.
    Trenkwalder, Claudia
    Adler, Charles H.
    Patni, Rajiv
    Johnson, Reed
    [J]. MOVEMENT DISORDERS CLINICAL PRACTICE, 2018, 5 (02): : 183 - 190
  • [29] Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
    Brigham, Elizabeth F.
    Johnston, Tom H.
    Brown, Carl
    Holt, Jonathon D. S.
    Fox, Susan H.
    Hill, Michael P.
    Howson, Patrick A.
    Brotchie, Jonathan M.
    Nguyen, Jack T.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 367 (02) : 373 - 381
  • [30] Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia
    Ronaghi, Abdolaziz
    Stan, Tiberiu Loredan
    Barrientos, Sebastian A.
    Halje, Par
    Nasretdinov, Azat
    Censoni, Luciano
    Sato, Sebastian Sulis
    Malinina, Evgenya
    Tedroff, Joakim
    Waters, Nicholas
    Petersson, Per
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2025, 61 (05)
12345